Author:
Colin Laurence,Smith Brian
Publisher
Springer International Publishing
Reference60 articles.
1. Tranter, E., Peters, G., Boyce, M. and Warrington, S. (2013), Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?. Br J Clin Pharmacol, 76: 164–172.
2. Eddleston M, Cohen, A. F., and Webb, D. J. (2016) Implications of the BIA-102474-101 study for review of first-into-human clinical trials. Br J Clin Pharmacol, 81: 582–586.
3. Müller M, ed. Clinical Pharmacology: Current Topics and Case Studies: New York, NY: Springer, 2016
4. Buoen, C., Bjerrum, O. J. and Thomsen, M. S. (2005), How First-Time-in-Human Studies Are Being Performed: A Survey of Phase I Dose-Escalation Trials in Healthy Volunteers Published Between 1995 and 2004. The Journal of Clinical Pharmacology, 45: 1123–1136.
5. “Version anglaise: Minutes of the Temporary Specialist Scientific Committee (TSSC) meeting on “FAAH (Fatty Acid Amide Hydrolase) Inhibitors” of 15/02/2016 (08/03/2016)” Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). 7 March 2016.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献